Looking at this filing, I need to identify the key facts. The filing is a Form 10-Q for Braveheart Bio, Inc. (NASDAQ:BRVE) for the quarterly period ended September 30, 2026. The filing is primarily a cover page and forward-looking statements cautionary note, with the substantive financial content referenced in the table of contents but not included in the extracted text. I do have enough substantive disclosure content to work with, including the company's identity, share count, clinical programs mentioned, and other facts from the cover page and cautionary note sections.

Braveheart Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of November 6, 2026, there were 89,870,352 shares of common stock, par value $0.0001 per share, outstanding.
  • Exchange listing: Common stock trades on The Nasdaq Global Market under the symbol BRVE.
  • Company classification: Braveheart Bio is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, according to the filing.
  • Lead program: The filing identifies BHB-1893 as the company's primary product candidate, with ongoing and planned clinical trials including LIONHEART-HCM, TRUEHEART-HCM, NOBLEHEART-HCM, and HEARTSONG-LTE.
  • China partner activity: According to the filing, Hengrui has an ongoing Phase 3 trial of BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM) in China.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Braveheart Bio's Clinical Pipeline and BHB-1893 Development Status

Braveheart Bio, Inc., a Delaware-incorporated biopharmaceutical company headquartered at One Letterman Drive, Building A, Suite A4-300, San Francisco, CA 94129, submitted its quarterly report for the period ended September 30, 2026, on NASDAQ:BRVE. The company's principal product candidate, BHB-1893, is the focus of multiple clinical programs in hypertrophic cardiomyopathy, a heart muscle disease. The filing references four named clinical trials: LIONHEART-HCM, TRUEHEART-HCM, NOBLEHEART-HCM, and HEARTSONG-LTE, as programs the company is monitoring for initiation, enrollment, progress, and data readouts.

The filing notes that Hengrui, the company's partner, is conducting an ongoing Phase 3 trial of BHB-1893 in oHCM in China, and that Braveheart Bio holds a collaboration and licensing relationship with Hengrui. According to the filing, the company interprets data from Hengrui's Phase 2 trials of BHB-1893, including a 52-week open-label extension and other exploratory and ad hoc analyses, while cautioning that "such data will be predictive of results in our ongoing and planned clinical trials" is a forward-looking matter subject to risks and uncertainties.

The filing states that forward-looking statements in the quarterly report cover topics including regulatory filings and approvals, capital sufficiency, manufacturing and supply, intellectual property, and commercial strategy for BHB-1893 and any future product candidates. The company notes that these forward-looking statements "are not guarantees of future performance or development" and are "subject to a number of risks, uncertainties and assumptions" described in the Risk Factors section of the quarterly report. The company did not elect to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act, according to the filing.

What Was Disclosed

Braveheart Bio, Inc. filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 89,870,352 shares outstanding as of November 6, 2026, its emerging growth company status, and the ongoing development of its lead candidate BHB-1893 across multiple named clinical programs.